

# **DRUG PRIOR AUTHORIZATION COMMITTEE**

*March 20, 2008*

## **TENTATIVE AGENDA**

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update PDL Process Discussion	Rhonda Driver/ Andrew Haslag
11:30 - 11:35	DUR Update	Tisha Honse

### **Old Business**

11:35 - 12:05	<b>a. Implementation Schedule</b> (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
	<b>b. New Drug Process Document</b>	

### **New Business**

12:05 – 12:20	New Drug/Product Reviews	
	<b>a. Proposed Actions</b> (See website and Attached Summary)	Rhonda Driver
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
12:20-1:45	<i>Proposed New Program Actions of Existing Products</i>	Rhonda Driver

- a. Drug List (PDL)**
- i. Antiemetics-Oral**
    - Discussion
    - Public Hearing
    - Decision
  - ii. *Beta Adrenergic Agents-Long Acting***
    - Discussion
    - Public Hearing
    - Decision
  - iii. *Beta Adrenergic Agents-Nebulized***
    - Discussion
    - Public Hearing
    - Decision
  - iv. *Beta Adrenergic Agents-Short Acting***
    - Discussion
    - Public Hearing
    - Decision
  - v. *Beta Blockers***
    - Discussion
    - Public Hearing
    - Decision
  - vi. *Calcium Channel Blockers/Dihydropyridines***
    - Discussion
    - Public Hearing
    - Decision
  - vii. *Calcium Channel Blockers/ Non-Dihydropyridines***
    - Discussion
    - Public Hearing
    - Decision
  - viii. *Calcium Channel Blocker/ARB Combinations***
    - Discussion
    - Public Hearing
    - Decision

- ix. **COPD Anticholinergics**
  - Discussion
  - Public Hearing
  - Decision
- x. **Cox II Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- xi. **Hematopoietic Agents**
  - Discussion
  - Public Hearing
  - Decision
- xii. **Hepatitis C Agents**
  - Discussion
  - Public Hearing
  - Decision
- xiii. **Inhaled Corticosteroids**
  - Discussion
  - Public Hearing
  - Decision
- xiv. **Insulins**
  - Discussion
  - Public Hearing
  - Decision
- xv. **Long Acting Insulins**
  - Discussion
  - Public Hearing
  - Decision
- xvi. **Rapid Acting Insulins**
  - Discussion
  - Public Hearing
  - Decision
- xvii. **Insulin-Mix**
  - Discussion
  - Public Hearing
  - Decision
- xviii. **Amylin Analogs**
  - Discussion
  - Public Hearing
  - Decision
- xix. **GLP -1 Receptor Agonists**
  - Discussion
  - Public Hearing
  - Decision
- xx. **DPP-IV Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- xxi. **Onychomycosis Antifungals**
  - Discussion
  - Public Hearing
  - Decision
- xxii. **Ophthalmic NSAIDS**
  - Discussion
  - Public Hearing
  - Decision
- xxiii. **Proton Pump Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- xxiv. **Ribavirins**
  - Discussion
  - Public Hearing
  - Decision
- xxv. **Sedative Hypnotics**
  - Discussion
  - Public Hearing
  - Decision

- xxvi. **Statins**
    - Discussion
    - Public Hearing
    - Decision
  - xxvii. **Topical Immunomodulators**
    - Discussion
    - Public Hearing
    - Decision
  - xxviii. **Triglyceride Lowering Agents**
    - Discussion
    - Public Hearing
    - Decision
  - xxix. **Urinary Tract Antispasmodics**
    - Discussion
    - Public Hearing
    - Decision
  - xxx. **Growth Hormones**
    - Discussion
    - Public Hearing
    - Decision
  - xxxi. **Androgen Hormone Inhibitors**
    - Discussion
    - Public Hearing
    - Decision
  - xxxii. **Non-Ergot Dopamine Receptor Agonists**
    - Discussion
    - Public Hearing
    - Decision
  - xxxiii. **Low Molecular Weight Heparins**
    - Discussion
    - Public Hearing
    - Decision
- c. **Preferred Drug List**
- i. Process discussion
  - ii. Therapeutic classes-to be *announced at meeting*

1:45

## **LUNCH**

2:00-2:20

## **Program Utilization Information**

Rhonda Driver

2:20-2:30

## **Other Business**

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, Agenda may move more quickly*

## **Executive Session**

2:30-2:35

Minutes Review

Discussion/Approval

2:35-3:00

Case Reviews

Rhonda Driver

**NEXT MEETING: June 21, 2007 – 205 Jefferson Street, 10<sup>th</sup> Floor.**